Don L. Gibbons, MD, PhD
Department of Thoracic-Head & Neck Med Onc, Division of Cancer Medicine
About Dr. Gibbons
Dr. Gibbons graduated from Harvard University in 1993 (BA degree in Biochemistry), and following completion of a MS degree at The University of Texas Health Science Center – San Antonio in 1996 and a MS degree at Albert Einstein College of Medicine in 1999, he obtained his MD and PhD degrees from Albert Einstein College of Medicine in 2004. Dr. Gibbons performed his Clinical Residency at Baylor College of Medicine before joining MD Anderson Cancer Center in 2006 as a Clinical Fellow and later as a Research Fellow and Instructor. In 2010, he was appointed Assistant Professor in the Department of Thoracic/Head and Neck Medical Oncology with a secondary appointment in the Department of Molecular and Cellular Oncology. Dr. Gibbons is a physician-scientist, specializing in lung cancer medical oncology and with a lab investigating the unique characteristics of tumor microenvironment in lung cancer and mechanisms that drive cancer cells to leave the primary tumor and spread to areas outside the lung. He was selected for the Physician Scientist Award (2012-2014) and the R. Lee Clark Fellowship (2014-2016), he was awarded the Young Physician-Scientist Award by the American Society of Clinical Investigation (ASCI, 2014) and recently elected as a member to ASCI. Dr. Gibbons is the Director of the Thoracic/Head and Neck Medical Oncology Translational Genetic Models Laboratory and Co-Leader of the Lung Cancer Moon Shot Program.
Read More
Present Title & Affiliation
Primary Appointment
Professor, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Associate Professor, Department of Molecular and Cellular Oncology, Division of Basic Science Research, The University of Texas MD Anderson Cancer Center, Houston, TX
Research Interests
Dr. Gibbons maintains a large and active research laboratory focused on understanding the regulation of cancer cell invasion and metastasis by intrinsic tumor cell factors and the role of the tumor microenvironment (immune cells and extracellular matrix) in those same processes. The team has specific expertise in understanding KRAS mutant lung cancer. In their studies the team uses human samples and clinical data, cell line models and mouse models. Recently, Dr. Gibbons demonstrated that for cancer cells to escape the primary lung tumor and colonize new organs, they need to suppress the immune system, a process that is mediated in part by suppression and exhaustion of T cell activity, which is coordinated in part by the protein PD-L1. Dr. Gibbons’ translational research suggests that immunotherapy may have anti-metastatic effects and has driven the development of new clinical trials, particularly in the area of acquired resistance to immunotherapy.
Clinical Interests
As a physician, Dr. Gibbons provides expert and compassionate clinical care to patients suffering from thoracic malignancies. He offers his patients both standard of care and clinical trial opportunities when available. Dr. Gibbons’ major clinical goals are to prevent the development of metastasis in lung cancer patients, i.e. to reduce the risk of cancer cells leaving the lung tumor and starting new tumors outside the lung; to develop new immunotherapy combinations for treatment of early-stage and metastatic disease; and to push forward the development of effective combination therapies for KRAS mutant lung cancer. His work focuses on understanding the role of the immune cells and other non-cancer cells (support cells) that are present in tumors in regulating tumor invasion, metastasis and treatment resistance. Dr. Gibbons is currently leading several clinical trials testing immunotherapy (anti-PD-1/PD-L1) alone and in combination with targeted agents for patients diagnosed with lung cancer.
Education & Training
Degree-Granting Education
| 2004 | Albert Einstein College of Medicine, Bronx, NY, USA, PHD, Cell Biology |
| 2004 | Albert Einstein College of Medicine, Bronx, NY, USA, MD, Medicine |
| 1999 | Albert Einstein College of Medicine, Bronx, NY, USA, MS, Cell Biology |
| 1996 | The University of Texas Health Science Center, San Antonio, TX, USA, MS, Biochemistry |
| 1993 | Harvard University, Cambridge, MA, USA, BA, Biochemistry |
Postgraduate Training
| 2007-2009 | Research Fellowship, The University of Texas MD Anderson Cancer Center, Houston, TX |
| 2006-2009 | Clinical Fellowship, Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX |
| 2004-2006 | Clinical Residency, MeRIT Scholars Program, Internal Medicine, Baylor College of Medicine, Houston, TX |
Board Certifications
| 2010 | Medical Oncology |
| 2007 | American Board of Internal Medicine |
Experience & Service
Academic Appointments
Associate Professor, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2016 - 2021
Selected Publications
Peer-Reviewed Articles
- Rocha P, Salazar R, Zhang J, Ledesma D, Solorzano JL, Mino B, Villalobos P, Dejima H, Douse DY, Diao L, Mitchell KG, Le X, Zhang J, Weissferdt A, Parra-Cuentas E, Cascone T, Rice DC, Sepesi B, Kalhor N, Moran C, Vaporciyan A, Heymach J, Gibbons DL, Lee JJ, Kadara H, Wistuba I, Behrens C, Solis LM. CD73 Expression Defines Immune, Molecular, and Clinicopathological Subgroups of Lung Adenocarcinoma. Cancer Immunol Immunother 70(7):1965-1976, 2021. e-Pub 2021. PMID: 33416944.
- Lam VK, Zhang J, Wu CC, Tran HT, Li L, Diao L, Wang J, Rinsurongkawong W, Raymond VM, Lanman RB, Lewis J, Roarty EB, Roth J, Swisher S, Lee JJ, Gibbons DL, Papadimitrakopoulou VA, Heymach JV. Genotype-specific Differences in Circulating Tumor DNA Levels in Advanced NSCLC. J Thorac Oncol 16(4):601-609, 2021. e-Pub 2020. PMID: 33388476.
- Le X, Negrao MV, Reuben A, Federico L, Diao L, McGrail D, Nilsson M, Robichaux J, Munoz IG, Patel S, Elamin Y, Fan YH, Lee WC, Parra E, Solis Soto LM, Chen R, Li J, Karpinets T, Khairullah R, Kadara H, Behrens C, Sepesi B, Wang R, Zhu M, Wang L, Vaporciyan A, Roth J, Swisher S, Haymaker C, Zhang J, Wang J, Wong KK, Byers LA, Bernatchez C, Zhang J, Wistuba II, Gibbons DL, Akbay EA, Heymach JV. Characterization of the Immune Landscape of EGFR-mutant NSCLC Identifies CD73/adenosine Pathway as a Potential Therapeutic Target. J Thorac Oncol 16(4):583-600, 2021. e-Pub 2020. PMID: 33388477.
- Ramkumar K, Stewart CA, Cargill KR, Della Corte CM, Wang Q, Shen L, Diao L, Cardnell RJ, Peng DH, Rodriguez BL, Fan YH, Heymach JV, Wang J, Gay CM, Gibbons DL, Byers LA. AXL Inhibition Induces DNA Damage and Replication Stress in Non-small Cell lung Cancer Cells and Promotes Sensitivity to ATR Inhibitors. Mol Cancer Res 19(3):485-497, 2021. e-Pub 2020. PMID: 33172976.
- Monteiro de Oliveira Novaes JA, Hirz T, Guijarro I, Nilsson M, Pisegna MA, Poteete A, Barsoumian HB, Fradette JJ, Chen LN, Gibbons DL, Tian X, Wang J, Myers JN, McArthur MJ, Bell D, William WN, Heymach JV. Targeting of CD40 and PD-L1 Pathways Inhibits Progression of Oral Premalignant Lesions in a Carcinogen-induced Model of Oral Squamous Cell Carcinoma. Cancer Prev Res (Phila) 14(3):313-324, 2021. e-Pub 2020. PMID: 33277316.
- Konen JM, Rodriguez BL, Padhye A, Ochieng JK, Gibson L, Diao L, Fowlkes NW, Fradette JJ, Peng DH, Cardnell RJ, Kovacs JJ, Wang J, Byers LA, Gibbons DL. Dual Inhibition of MEK and AXL Targets Tumor Cell Heterogeneity and Prevents Resistant Outgrowth Mediated by the Epithelial-to-mesenchymal Transition in NSCLC. Cancer Res 81(5):1398-1412, 2021. e-Pub 2021. PMID: 33402388.
- Tan X, Shi L, Banerjee P, Liu X, Guo HF, Yu J, Bota-Rabassedas N, Rodriguez BL, Gibbons DL, Russell WK, Creighton CJ, Kurie JM. A Pro-tumorigenic Secretory Pathway Activated by p53 Deficiency in Lung Adenocarcinoma. J Clin Invest 131(1), 2021. e-Pub 2020. PMID: 32931483.
- Creelan BC, Yeh TC, Kim SW, Nogami N, Kim DW, Chow LQM, Kanda S, Taylor R, Tang W, Tang M, Angell HK, Roudier MP, Marotti M, Gibbons DL. A Phase 1 Study of Gefitinib Combined with Durvalumab in EGFR TKI-naive Patients with EGFR Mutation-positive Locally Advanced/metastatic Non-small-cell Lung Cancer. Br J Cancer 124(2):383-390, 2021. e-Pub 2020. PMID: 33012782.
- Gaudreau PO, Negrao MV, Mitchell KG, Reuben A, Corsini EM, Li J, Karpinets TV, Wang Q, Diao L, Wang J, Federico L, Parra-Cuentas ER, Khairullah R, Behrens C, Correa AM, Gomez D, Little L, Gumbs C, Kadara HN, Fujimoto J, McGrail DJ, Vaporciyan AA, Swisher SG, Walsh G, Antonoff MB, Weissferdt A, Tran H, Roarty E, Haymaker C, Bernatchez C, Zhang J, Futreal PA, Wistuba II, Cascone T, Heymach JV, Sepesi B, Zhang J, Gibbons DL. Neoadjuvant Chemotherapy Increases Cytotoxic T Cell, Tissue Resident Memory T Cell, and B Cell Infiltration in Resectable NSCLC. J Thorac Oncol 16(1):127-139, 2021. e-Pub 2020. PMID: 33096269.
- Pradhan M, Chocry M, Gibbons DL, Sepesi B, Cascone T. Emerging Biomarkers for Neoadjuvant Immune Checkpoint Inhibitors in Operable Non-small Cell Lung Cancer. Transl Lung Cancer Res 10(1):590-606, 2021. e-Pub 2020. PMID: 33569339.
- Lee WC, Reuben A, Hu X, McGranahan N, Chen R, Jalali A, Negrao MV, Hubert SM, Tang C, Wu CC, Lucas AS, Roh W, Suda K, Kim J, Tan AC, Peng DH, Lu W, Tang X, Chow CW, Fujimoto J, Behrens C, Kalhor N, Fukumura K, Coyle M, Thornton R, Gumbs C, Li J, Wu CJ, Little L, Roarty E, Song X, Lee JJ, Sulman EP, Rao G, Swisher S, Diao L, Wang J, Heymach JV, Huse JT, Scheet P, Wistuba II, Gibbons DL, Futreal PA, Zhang J, Gomez D, Zhang J. Multiomics Profiling of Primary Lung Cancers and Distant Metastases Reveals Immunosuppression as a Common Characteristic of Tumor Cells with Metastatic Plasticity. Genome Biol 21(1):271, 2020. e-Pub 2020. PMID: 33148332.
- Gay CM, Zhou Y, Lee JJ, Tang XM, Lu W, Wistuba II, Ferrarotto R, Gibbons DL, Glisson BS, Kies MS, Simon GR, Heymach JV, Tsao AS. A Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma. Oncologist 25(10):e1457-e1463, 2020. e-Pub 2020. PMID: 32608142.
- Ochieng JK, Kundu ST, Bajaj R, Leticia Rodriguez B, Fradette JJ, Gibbons DL. MBIP (MAP3K12 binding inhibitory protein) Drives NSCLC Metastasis by JNK-dependent Activation of MMPs. Oncogene 39(43):6719-6732, 2020. e-Pub 2020. PMID: 32963352.
- Hong L, Negrao MV, Dibaj SS, Chen R, Reuben A, Bohac JM, Liu X, Skoulidis F, Gay CM, Cascone T, Mitchell KG, Tran HT, Le X, Byers LA, Sepesi B, Altan M, Elamin YY, Fossella FV, Kurie JM, Lu C, Mott FE, Tsao AS, Rinsurongkawong W, Lewis J, Gibbons DL, Glisson BS, Blumenschein GR, Roarty EB, Futreal PA, Wistuba II, Roth JA, Swisher SG, Papadimitrakopoulou VA, Heymach JV, Lee JJ, Simon GR, Zhang J. Programmed Death Ligand 1 Heterogeneity and its Impact on Benefit from Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer. J Thorac Oncol 15(9):1449-1459, 2020. e-Pub 2020. PMID: 32389639.
- Yamauchi M, Gibbons DL, Zong C, Fradette JJ, Bota-Rabassedas N, Kurie JM. Fibroblast Heterogeneity and its Impact on Extracellular Matrix and Immune Landscape Remodeling in Cancer. Matrix Biol 91-92:8-18, 2020. e-Pub 2020. PMID: 32442601.
- Nilsson MB, Sun H, Robichaux J, Pfeifer M, McDermott U, Travers J, Diao L, Xi Y, Tong P, Shen L, Hofstad M, Kawakami M, Le X, Liu X, Fan Y, Poteete A, Hu L, Negrao MV, Tran H, Dmitrovsky E, Peng D, Gibbons DL, Wang J, Heymach JV. A YAP/FOXM1 Axis Mediates EMT-associated EGFR Inhibitor Resistance and Increased Expression of Spindle Assembly Checkpoint Components. Sci Transl Med 12(559), 2020. PMID: 32878980.
- Bajaj R, Kundu ST, Grzeskowiak CL, Fradette JJ, Scott KL, Creighton CJ, Gibbons DL. IMPAD1 and KDELR2 Drive Invasion and Metastasis by Enhancing Golgi-mediated Secretion. Oncogene 39(37):5979-5994, 2020. e-Pub 2020. PMID: 32753652.
- Peng DH, Rodriguez BL, Diao L, Chen L, Wang J, Byers LA, Wei Y, Chapman HA, Yamauchi M, Behrens C, Raso G, Soto LMS, Cuentes ERP, Wistuba II, Kurie JM, Gibbons DL. Collagen Promotes Anti-PD-1/PD-L1 Resistance in Cancer Through LAIR1-dependent CD8+ T Cell Exhaustion. Nat Commun 11(1):4520, 2020. e-Pub 2020. PMID: 32908154.
- Mitchell KG, Amini B, Wang Y, Carter BW, Godoy MCB, Parra ER, Behrens C, Villalobos P, Reuben A, Lee JJ, Weissferdt A, Moran CA, Fujimoto J, Sepesi B, Walsh GL, Vaporciyan AA, Hofstetter WL, William WN, Gibbons DL, Wang J, Hwu P, Swisher SG, Piwnica-Worms D, Kadara H, Wistuba II, Heymach JV, Peng W, Cascone T. 18F-fluorodeoxyglucose Positron Emission Tomography Correlates with Tumor Immunometabolic Phenotypes in Resected Lung Cancer. Cancer Immunol Immunother 69(8):1519-1534, 2020. e-Pub 2020. PMID: 32300858.
- Gaudreau PO, Lee JJ, Heymach JV, Gibbons DL. Phase I/II Trial of Immunotherapy With Durvalumab and Tremelimumab With Continuous or Intermittent MEK Inhibitor Selumetinib in NSCLC: Early Trial Report. Clin Lung Cancer 21(4):384-388, 2020. e-Pub 2020. PMID: 32299768.
- Cascone T, Sepesi B, Lin HY, Kalhor N, Parra ER, Jiang M, Godoy MCB, Zhang J, Fossella FV, Tsao AS, Lam VK, Lu C, Mott FE, Simon GR, Antonoff MB, Mehran RJ, Rice DC, Behrens C, Weissferdt A, Moran C, Vaporciyan AA, Lee JJ, Swisher SG, Gibbons DL, Wistuba II, William WN, Heymach JV. A Phase I/II Study of Neoadjuvant Cisplatin, Docetaxel and Nintedanib for Resectable Non-Small Cell Lung Cancer. Clin Cancer Res 26(14):3525-3536, 2020. e-Pub 2020. PMID: 32193228.
- Della Corte CM, Sen T, Gay CM, Ramkumar K, Diao L, Cardnell RJ, Rodriguez BL, Stewart CA, Papadimitrakopoulou VA, Gibson L, Fradette JJ, Wang Q, Fan Y, Peng DH, Negrao MV, Wistuba II, Fujimoto J, Solis Soto LM, Behrens C, Skoulidis F, Heymach JV, Wang J, Gibbons DL, Byers LA. STING Pathway Expression Identifies NSCLC with an Immune-Responsive Phenotype. J Thorac Oncol 15(5):777-791, 2020. e-Pub 2020. PMID: 32068166.
- Mitchell KG, Diao L, Karpinets T, Negrao MV, Tran HT, Parra ER, Corsini EM, Reuben A, Federico L, Bernatchez C, Dejima H, Francisco-Cruz A, Wang J, Antonoff MB, Vaporciyan AA, Swisher SG, Cascone T, Wistuba II, Heymach JV, Gibbons DL, Zhang J, Haymaker CL, Sepesi B. Neutrophil Expansion Defines an Immunoinhibitory Peripheral and Intratumoral Inflammatory Milieu in Resected Non-small Cell Lung Cancer: A Descriptive Analysis of a Prospectively Immunoprofiled Cohort. J Immunother Cancer 8(1), 2020. PMID: 32350118.
- Mitchell KG, Negrao MV, Parra ER, Li J, Zhang J, Dejima H, Vaporciyan AA, Swisher SG, Weissferdt A, Antonoff MB, Cascone T, Roarty E, Wistuba II, Heymach JV, Gibbons DL, Zhang J, Sepesi B. Lymphovascular Invasion is Associated with Mutational Burden and PD-L1 in Resected Lung Cancer. Ann Thorac Surg 109(2):358-366, 2020. e-Pub 2019. PMID: 31550464.
- Lin SH, Lin Y, Yao L, Kalhor N, Carter BW, Altan M, Blumenschein G, Byers LA, Fossella F, Gibbons DL, Kurie JM, Lu C, Simon G, Skoulidis F, Chang JY, Jeter MD, Liao Z, Gomez DR, O'Reilly M, Papadimitrakopoulou V, Thall P, Heymach JV, Tsao AS. Phase II Trial of Concurrent Atezolizumab with Chemoradiation for Unresectable NSCLC. J Thorac Oncol 15(2):248-257, 2020. e-Pub 2019. PMID: 31778797.
- Tan X, Banerjee P, Pham EA, Rutaganira FUN, Basu K, Bota-Rabassedas N, Guo HF, Grzeskowiak CL, Liu X, Yu J, Shi L, Peng DH, Rodriguez BL, Zhang J, Zheng V, Duose DY, Solis LM, Mino B, Raso MG, Behrens C, Wistuba II, Scott KL, Smith M, Nguyen K, Lam G, Choong I, Mazumdar A, Hill JL, Gibbons DL, Brown PH, Russell WK, Shokat K, Creighton CJ, Glenn JS, Kurie JM. PI4KIIIβ is a Therapeutic Target in Chromosome 1q-amplified Lung Adenocarcinoma. Sci Transl Med 12(527), 2020. PMID: 31969487.
- Reuben A, Zhang J, Chiou SH, Gittelman RM, Li J, Lee WC, Fujimoto J, Behrens C, Liu X, Wang F, Quek K, Wang C, Kheradmand F, Chen R, Chow CW, Lin H, Bernatchez C, Jalali A, Hu X, Wu CJ, Eterovic AK, Parra ER, Yusko E, Emerson R, Benzeno S, Vignali M, Wu X, Ye Y, Little LD, Gumbs C, Mao X, Song X, Tippen S, Thornton RL, Cascone T, Snyder A, Wargo JA, Herbst R, Swisher S, Kadara H, Moran C, Kalhor N, Zhang J, Scheet P, Vaporciyan AA, Sepesi B, Gibbons DL, Robins H, Hwu P, Heymach JV, Sharma P, Allison JP, Baladandayuthapani V, Lee JJ, Davis MM, Wistuba II, Futreal PA, Zhang J. Comprehensive T Cell Repertoire Characterization of Non-small Cell Lung Cancer. Nat Commun 11(1):603, 2020. e-Pub 2020. PMID: 32001676.
- Zhang X, Zhang R, Chen H, Wang L, Ren C, Pataer A, Wu S, Meng QH, Ha MJ, Morris J, Xi Y, Wang J, Zhang J, Gibbons DL, Heymach JV, Meric-Bernstam F, Minna J, Swisher SG, Roth JA, Fang B. KRT-232 and Navitoclax Enhance Trametinib's Anti-Cancer Activity in Non-small Cell Lung Cancer Patient-derived Xenografts with KRAS Mutations. Am J Cancer Res 10(12):4464-4475, 2020. e-Pub 2020. PMID: 33415011.
- Sepesi B, Nelson DB, Mitchell KG, Gibbons DL, Heymach JV, Vaporciyan AA, Swisher SG, Roszik J. Prognostic Value of PD-L1 mRNA Sequencing Expression Profile in Non-Small Cell Lung Cancer. Ann Thorac Surg 105(6):1621-1626, 2018. e-Pub 2018. PMID: 29510096.
- Chen F, Zhang Y, Gibbons DL, Deneen B, Kwiatkowski DJ, Ittmann M, Creighton CJ. Pan-cancer Molecular Classes Transcending Tumor Lineage across 32 Cancer Types, Multiple Data Platforms, and over 10,000 Cases. Clin Cancer Res 24(9):2182-2193, 2018. e-Pub 2018. PMID: 29440175.
- Tan X, Banerjee P, Liu X, Yu J, Gibbons DL, Wu P, Scott KL, Diao L, Zheng X, Wang J, Jalali A, Suraokar M, Fujimoto J, Behrens C, Liu X, Liu CG, Creighton CJ, Wistuba II, Kurie JM. The Epithelial-to-Mesenchymal Transition Activator ZEB1 Initiates a Prometastatic Competing Endogenous RNA Network. J Clin Invest 128(4):1267-1282, 2018. e-Pub 2018. PMID: 29324442.
- Gibbons DL, Creighton CJ. Pan-cancer Survey of Epithelial-Mesenchymal Transition Markers across the Cancer Genome Atlas. Dev Dyn 247(3):555-564, 2018. e-Pub 2017. PMID: 28073171.
- Yamauchi M, Barker TH, Gibbons DL, Kurie JM. The Fibrotic Tumor Stroma. J Clin Invest 128(1):16-25, 2018. e-Pub 2018. PMID: 29293090.
- Yan X, Wang L, Zhang R, Pu X, Wu S, Yu L, Meraz IM, Zhang X, Wang JF, Gibbons DL, Mehran RJ, Swisher SG, Roth JA, Fang B. Overcoming Resistance to Anti-PD Immunotherapy in a Syngeneic Mouse Lung Cancer Model Using Locoregional Virotherapy. Oncoimmunology 7(1):e1376156, 2017. e-Pub 2017. PMID: 29296537.
- Lou Y, Diao L, Cuentas ER, Denning WL, Chen L, Fan YH, Byers LA, Wang J, Papadimitrakopoulou VA, Behrens C, Rodriguez JC, Hwu P, Wistuba II, Heymach JV, Gibbons DL. Epithelial-Mesenchymal Transition is Associated with a Distinct Tumor Microenvironment Including Elevation of Inflammatory Signals and Multiple Immune Checkpoints in Lung Adenocarcinoma. Clin Cancer Res 22(14):3630-42, 2016. e-Pub 2016. PMID: 26851185.
- Zhang T, Guo L, Creighton CJ, Lu Q, Gibbons DL, Yi ES, Deng B, Molina JR, Sun Z, Yang P, Yang Y. A Genetic Cell Context-Dependent Role for ZEB1 in Lung Cancer. Nat Commun 7:12231, 2016. e-Pub 2016. PMID: 27456471.
- Mak MP, Tong P, Diao L, Cardnell RJ, Gibbons DL, William WN, Skoulidis F, Parra ER, Rodriguez-Canales J, Wistuba II, Heymach JV, Weinstein JN, Coombes KR, Wang J, Byers LA. A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial to Mesenchymal Transition. Clin Cancer Res 22(3):609-20, 2016. e-Pub 2015. PMID: 26420858.
- Kundu ST, Byers LA, Peng DH, Roybal JD, Diao L, Wang J, Tong P, Creighton CJ, Gibbons DL. The Mir-200 Family and the Mir-183~96~182 Cluster Target Foxf2 to Inhibit Invasion and Metastasis in Lung Cancers. Oncogene 35(2):1-14, 2016. e-Pub 2015. PMID: 25798833.
- Ungewiss C, Rizvi ZH, Roybal JD, Peng DH, Gold KA, Shin DH, Creighton CJ, Gibbons DL. The MicroRNA-200/Zeb1 Axis Regulates ECM-Dependent Β1-Integrin/FAK Signaling, Cancer Cell Invasion and Metastasis through CRKL. Sci Rep 6:18652, 2016. e-Pub 2016. PMID: 26728244.
- Gibbons DL, Byers LA. A HER 1-2 Punch: Dual EGFR Targeting Deals Resistance a Deadly Blow. Cancer Discov 4(9):991-4, 2014. PMID: 25185188.
- Yang Y, Ahn YH, Chen Y, Tan X, Guo L, Gibbons DL, Ungewiss C, Peng DH, Liu X, Lin SH, Thilaganathan N, Wistuba II, Rodriguez-Canales J, McLendon G, Creighton CJ, Kurie JM. ZEB1 Sensitizes Lung Adenocarcinoma to Metastasis Suppression by PI3K Antagonism. J Clin Invest 124(6):2696-708, 2014. e-Pub 2014. PMID: 24762440.
- Gibbons DL, Byers LA, Kurie JM. Smoking, p53 Mutation, and Lung Cancer. Mol Cancer Res 12(1):3-13, 2014. PMID: 24442106.
- Chen L, Gibbons DL, Goswami S, Cortez MA, Ahn YH, Byers LA, Zhang X, Yi X, Dwyer D, Lin W, Diao L, Wang J, Roybal JD, Patel M, Ungewiss C, Peng D, Antonia S, Mediavilla-Varela M, Robertson G, Jones S, Suraokar M, Welsh JW, Erez B, Wistuba II, Chen L, Peng D, Wang S, Ullrich SE, Heymach JV, Kurie JM, Qin FX. Metastasis is Regulated via Microrna-200/ZEB1 Axis Control of Tumour Cell PD-L1 Expression and Intratumoral Immunosuppression. Nat Commun 5:5241, 2014. e-Pub 2014. PMID: 25348003.
- Creighton CJ, Gibbons DL, Kurie JM. The Role of Epithelial-Mesenchymal Transition Programming in Invasion and Metastasis: A Clinical Perspective. Cancer Manag Res 5:187-95, 2013. e-Pub 2013. PMID: 23986650.
- Gill BJ, Gibbons DL, Roudsari LC, Saik JE, Rizvi ZH, Roybal JD, Kurie JM, West JL†. A Synthetic Matrix with Independently Tunable Biochemistry and Mechanical Properties to Study Epithelial Morphogenesis and EMT in a Lung Adenocarcinoma Model. Cancer Res 72(22):6013-23, 2012. e-Pub 2012. PMID: 22952217.
- Ahn YH, Gibbons DL, Chakravarti D, Creighton CJ, Rizvi ZH, Adams HP, Pertsemlidis A, Gregory PA, Wright JA, Goodall GJ, Flores ER, Kurie JM. ZEB1 Drives Prometastatic Actin Skeletal Remodeling by Downregulating miR-34a Expression. J Clin Invest 122(9):3170-83, 2012. e-Pub 2012. PMID: 22850877.
- Schliekelman MJ, Gibbons DL, Faca VM, Creighton CJ, Rizvi ZH, Zhang Q, Wong CH, Wang H, Ungewiss C, Ahn YH, Shin DH, Kurie JM, Hanash SM. Targets of the Tumor Suppressor miR-200 in Regulation of the Epithelial-mesenchymal Transition in Cancer. Cancer Res 71(24):7670-82, 2011. e-Pub 2011. PMID: 21987723.
- Yang Y, Ahn YH, Gibbons DL, Zang Y, Lin W, Thilaganathan N, Alvarez CA, Moreira DC, Creighton CJ, Gregory PA, Goodall GJ, Kurie JM. The Notch Ligand Jagged 2 Promotes Tumor Metastasis by Activating a Double-negative Feedback Loop Involving GATA3 and MicroRNA-200. J Clin Invest 121(4):1373-85, 2011. e-Pub 2011. PMID: 21403400.
- Cataldo VD, Gibbons DL, Pérez-Soler R, Quintás-Cardama A. Treatment of Non-small-cell Lung Cancer with Erlotinib or Gefitinib. N Engl J Med 364(10):947-55, 2011. PMID: 21388312.
- Gibbons DL, Lin W, Creighton CJ, Rizvi ZH, Gregory PA, Goodall GJ, Thilaganathan N, Du L, Zhang Y, Pertsemlidis A, Kurie JM. Contextual Extracellular Cues Promote Tumor Cell EMT and Metastasis by Regulating miR-200 Family Expression. Genes Dev 23(18):2140-51, 2009. PMID: 19759262.